Daiichi Sankyo Co Ltd 2016 Integrated Report
The report shows Daiichi Sankyo Group revenue of ¥986.4 billion in fiscal 2015 and outlines its transformation toward a global pharma innovator with competitive advantage in oncology. It describes CSR activities integrated with business operations across compliance, employees, stakeholders, environmental management, healthcare access, and social contribution. Environmental priorities include a group-wide fiscal 2020 CO2 reduction target of 5.6% from fiscal 2015. The report also provides consolidated ESG data, including emissions, water, waste, workforce, and governance information.
Company: Daiichi Sankyo Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2016
Type: Integrated Report
Pages: 53
Back to company
Daiichi Sankyo Co Ltd
Value Report
The report shows Daiichi Sankyo Group revenue of ¥986.4 billion in fiscal 2015 and outlines its transformation toward a global pharma innovator with competitive advantage in oncology. It describes CSR activities integrated with business operations across compliance, employees, stakeholders, environmental management, healthcare access, and social contribution. Environmental priorities include a group-wide fiscal 2020 CO2 reduction target of 5.6% from fiscal 2015. The report also provides consolidated ESG data, including emissions, water, waste, workforce, and governance information.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Apr 1, 2015 - Mar 31, 2016
Fiscal Year
2015
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Women in Management
Employees